KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Operating Income: 2013-2025

Historic Operating Income for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to -$96.3 million.

  • Xenon Pharmaceuticals' Operating Income fell 30.76% to -$96.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$340.8 million, marking a year-over-year decrease of 33.37%. This contributed to the annual value of -$279.3 million for FY2024, which is 30.48% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Operating Income stood at -$96.3 million, which was down 2.24% from -$94.2 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Operating Income high stood at -$15.6 million for Q3 2021, and its period low was -$96.3 million during Q3 2025.
  • Over the past 3 years, Xenon Pharmaceuticals' median Operating Income value was -$69.1 million (recorded in 2024), while the average stood at -$68.8 million.
  • Data for Xenon Pharmaceuticals' Operating Income shows a maximum YoY crashed of 3,382.66% (in 2021) over the last 5 years.
  • Xenon Pharmaceuticals' Operating Income (Quarterly) stood at -$24.8 million in 2021, then plummeted by 74.45% to -$43.3 million in 2022, then decreased by 23.92% to -$53.7 million in 2023, then slumped by 44.29% to -$77.5 million in 2024, then slumped by 30.76% to -$96.3 million in 2025.
  • Its Operating Income stands at -$96.3 million for Q3 2025, versus -$94.2 million for Q2 2025 and -$72.7 million for Q1 2025.